Biotech & Pharma Updates | February 24 - 25, 2026
🧬 Novartis selects Denton, Texas for fifth US radiopharmaceutical facility - generating $280M investment and 175 jobs, BreezeBio raises $60M Series B - genetic medicines using specialized nanoparticles, Novo Nordisk + Vivtex collaborate on oral biologics for obesity, up to $2.1B in milestones, Gilead's bictegravir/lenacapivir combo shows Ph2/3 non-inferiority results for human immunodeficiency virus treatment, GSK to buy 35Pharma for $950M - gaining pulmonary hypertension hopeful HS235, Pfizer + Beam Therapeutics global license for liver-targeted gene editing candidate - $1.05B milestone potential
